Bellevue Group »

Bridgebio Oncology Therapeut shares owned by Bellevue Group

Quarter-by-quarter ownership of Bridgebio Oncology Therapeut (BBOT) shares owned by Bellevue Group from 13F filings

Historical chart of Bellevue Group investment in Bridgebio Oncology Therapeut

Tip: Access up to 7 years of quarterly data

All positions including Bridgebio Oncology Therapeut held by Bellevue Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bridgebio Oncology Therapeut by Bellevue Group

Quarter filed Position value Share count Share price at filing
2026-03-31 $63k 7.0k 8.95

More positions owned by Bellevue Group

Vertex Pharmaceuticals Incorporated (VRTX)
Argenx Se Sponsored Adr (ARGX)
Regeneron Pharmaceuticals (REGN)
Scholar Rock Hldg Corp (SRRK)
Gilead Sciences (GILD)
Revolution Medicines (RVMD)
Ionis Pharmaceuticals (IONS)
Intuitive Surgical Com New (ISRG)
Miragen Therapeutics (VRDN)
Krystal Biotech (KRYS)
Crinetics Pharmaceuticals In (CRNX)
Abbott Laboratories (ABT)
Nuvalent Inc-a (NUVL)
Amgen (AMGN)
Boston Scientific Corporation (BSX)

View all positions for Bellevue Group

Top funds holding Bridgebio Oncology Therapeut

Cormorant Asset Management
Deerfield Management Company
Omega Fund Management
Alphabet
EcoR1 Capital
Wellington Management Company
Enavate Sciences GP
Citadel Advisors
Novo A/S
BlackRock
Laurion Capital Management
Armistice Capital
Aisling Capital Management
Paradigm Biocapital Advisors
Octagon Capital Advisors

View all funds holding Bridgebio Oncology Therapeut